Skip to content 
Pancreatic cancer pain is among the most severe pain encountered in oncology, caused by tumour invasion of the celiac plexus, ductal obstruction, and inflammation in surrounding tissues. Management uses a layered approach, starting with non-opioid analgesia, moving through opioid medication, and adding interventional procedures like EUS-guided celiac neurolysis when standard treatment isn’t enough. The goal isn’t only pain reduction. It is functional quality of life, the ability to eat, sleep, and spend time meaningfully. Many patients have their pain undertreated for months before someone takes it seriously enough to escalate appropriately.
According to Dr. Vipulroy Rathod, Gastroenterologist in Mumbai, “Pancreatic cancer pain is different from most other pains, and treating it like it’s the same as back pain or arthritis is where things go wrong. It needs early opioid use, often combined with adjuvants, and procedural pain blocks much earlier than they tend to be offered. Patients shouldn’t have to wait until the pain is unbearable before someone tries something different.”
What are the layered approach to pain management?
Pancreatic cancer pain isn’t controlled by any single medication or procedure. It needs several treatments working alongside each other, escalating as the disease progresses.
- Non-opioid analgesia as the baseline. Paracetamol and NSAIDs in the early stages, though NSAIDs are limited by kidney function and bleeding risk in many cancer patients. Useful when the pain is still moderate.
- Opioid medication is started earlier in pancreatic cancer than in most other conditions. Oral morphine, oxycodone, or fentanyl patches, with breakthrough doses available for flare-ups. The fear of starting opioids early is misplaced in this disease, the issue is usually undertreatment, not addiction.
- Adjuvant medications. Gabapentin or pregabalin for the neuropathic component, tricyclic antidepressants in some cases, and corticosteroids for short-term pain flares. These often allow lower opioid doses than would otherwise be needed.
- EUS-guided celiac plexus neurolysis for pain that doesn’t respond to medical management. Alcohol injection around the celiac plexus permanently interrupts pain signals from the upper abdomen, with relief lasting weeks to months and often the rest of the patient’s illness.
Choosing the right combination depends on where the patient is in their disease and how much function they still have. Pancreatic cancer treatment planning at every stage should include pain management as part of the discussion, not an afterthought once everything else has been settled.
What changes through the disease course?
Pain management isn’t static. The drugs that worked early often stop working, and what’s needed evolves with the disease.
- Early disease, mild-moderate pain. Paracetamol, NSAIDs where safe, low-dose opioids for breakthrough. Many patients are managed on relatively modest medication during the first few months after diagnosis if chemotherapy is shrinking the tumour or controlling growth.
- As the disease progresses, opioid doses usually need to rise. Pain that was manageable on twenty milligrams of morphine a day might need eighty or more six months later. Rotation between different opioids is often used when tolerance develops to one specific drug.
- The point where celiac neurolysis should be considered. Patients on rising opioid doses with breakthrough pain, side effects from medication, and a quality of life that’s eroding because of the pain itself, not just the cancer. This is usually weeks or months earlier than it actually gets offered in most centres.
- End-of-life pain management. Subcutaneous opioid infusions, syringe drivers for continuous dosing, and palliative care integration. By this stage the focus is comfort and symptom control rather than function.
The aim throughout is to keep pain controlled without trading too much of the patient’s alertness or quality of life for that control. Read more on pancreatic cancer detection to understand why so many cases are picked up at stages where pain management becomes a major part of the conversation from the start.
Why choose Dr. Vipulroy Rathod for pancreatic cancer pain management?
Dr. Vipulroy Rathod has been managing pancreatic cancer pain at Fortis Hospital Mulund for over three decades, with particular focus on EUS-guided celiac plexus neurolysis and the procedural side of pain management that most centres don’t offer routinely. Many patients arrive on rising opioid doses with poor pain control, having never been offered celiac neurolysis as an option earlier in their illness.
Pain in this disease deserves the same attention as the cancer itself. Patients spending their last months in unrelieved pain because no one referred them for a celiac block is, frankly, a system failure rather than a clinical limit. The block isn’t experimental or last-resort, it’s a procedure that’s been available for decades and works.
Book your consultation today with one of India’s most experienced specialists for pancreatic disease pain management and procedural intervention.
Frequently Asked Questions
The pancreas sits close to the celiac plexus, a major bundle of nerves carrying visceral pain signals. Tumour invasion of this plexus directly produces some of the most intense pain encountered in cancer, often poorly controlled by standard analgesics without procedural intervention.
Earlier than it usually is. Rising opioid doses, breakthrough pain not controlled by medication, side effects affecting quality of life, all of these are signs the procedure should be on the table. Waiting until pain is unbearable is the common mistake.
Addiction is rarely a meaningful concern in pancreatic cancer pain management. Physical dependence develops, but that’s different from addiction, and the priority is pain control rather than minimising opioid exposure. Undertreatment harms more patients than overuse does.
No, the two run in parallel. Good pain control actually helps patients tolerate chemotherapy better and stay functional longer, which can improve overall survival. Pain management isn’t a separate track from cancer treatment, it’s part of the same plan.
Reference links-
- EUS-guided celiac plexus neurolysis — https://ascopubs.org/doi/10.1200/JCO.2010.32.2750 (JCO trial on early EUS-CPN in pancreatic cancer)
- WHO ladder & cancer pain management — https://www.annalsofoncology.org/article/S0923-7534(19)31698-9/fulltext (ESMO Clinical Practice Guidelines)
